MiR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages E204-E213

  Huang, Chen ^a   Cai, Zhaogeng ^b   Huang, Mingzhu ^d   Mao, Chaoming ^e   Zhang, Qifa ^c,f   Lin, Yi ^a   Zhang, Xiaomei ^b   Tang, Bi ^b   Chen, Yuqing ^b   Wang, Xiaojing ^b   Qian, Zhongqing ^b   Ye, Lei ^g   Peng, Yongde ^a   Xu, Huanbai ^a,b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b BENGBU MEDICAL COLLEGE   (China)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^f Shanghai Hospital of Integrated Traditional Chinese and Western Medicine   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MICRORNA; MICRORNA 219 5P; UNCLASSIFIED DRUG; MIRN219 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THYROID CARCINOMA; TUMOR VOLUME; UPREGULATION; CELL MOTION; GENETICS; METABOLISM; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; THYROID NEOPLASMS;

EID: 84928318119     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2883     Document Type: Article

References (26)

1. Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors. Endocr Pathol. 2011; 22: 126-133.
2. Massoni F, Simeone C, Ricci P, Onofri E, Ricci S. Papillary thyroid carcinoma and medicolegal considerations. Minerva Med. 2013; 104: 493-494.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
4. LiVolsi VA Papillary thyroid carcinoma: an update. Mod Pathol. 2011; 24(Suppl. 2): S1-S9.
5. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002; 227-247.
6. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007; 148: 936-941.
7. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22: 4578-4580.
8. Mazzaferri EL Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 2000; 6: 469-476.
9. Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
10. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350-355.
11. Rhoades MW, Reinhart BJ, Lim LP, Burge CB, Bartel B, Bartel DP. Prediction of plant microRNA targets. Cell. 2002; 110: 513-520.
12. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005; 102: 19075-19080.
13. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006; 13: 497-508.
14. Lv M, Zhang X, Li M, et al. miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma. PLoS One. 2013; 8: e67591.
15. Zhang X, Li D, Li M, et al. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Int J Cancer. 2014; 134: 257-267.
16. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14: 791-798.
17. Huang N, Lin J, Ruan J, et al. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012; 586: 884-891.
18. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 2009; 23: 806-812.
19. Rao SA, Arimappamagan A, Pandey P, et al. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One. 2013; 8: e63164.
20. Gong L, Chen P, Liu X, et al. Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma. Gland Surg. 2012; 1: 25-32.
21. Blander CL Estrogens and breast cancer. N Engl J Med. 2006; 354: 1647-1648; author reply 1647-1648.
22. Klinge CM Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001; 29: 2905-2919.
23. Chu R, van Hasselt A, Vlantis AC, et al. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer. 2014; 120: 142-153.
24. Cho MA, Lee MK, Nam KH, et al. Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol. 2007; 195: 255-263.
25. Clark OH, Gerend PL, Davis M, Goretzki PE, Hoffman PG Jr Estrogen and thyroid-stimulating hormone (TSH) receptors in neoplastic and nonneoplastic human thyroid tissue. J Surg Res. 1985; 38: 89-96.
26. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011; 5: 51-56.